Manganese Revisited
Member-Initiated Session
Thursday, 15 May 2025
Session Number: MIS-08
No CME/CE Credit
Overview:
Manganese-enhanced MRI (MEMRI) has been known for several decades in
particular due to the seminal work by the group of Alan Koretsky.
However, it always eked out a shadowy existence in the face of
overwhelming applications of Gd-based contrast agents. Recent progress
in the design of Mn-based agents and the increasing concerns about Gd
deposition in the brain of patients frequently subjected to Gd
investigations reinvigorated the interest in MEMRI culminating in the
imminent approval of the first clinical Mn-based contrast agent.
Importantly, in contrast to Gd, Mn is a physiologically occurring trace
element with evolutionarily evolved clearance pathways. The current
session will give an overview about the recent ups and downs of MEMRI
and will open the view for new exciting applications of this still
slumbering powerful contrast agent approach.
Target Audience:
Radiologists and MRI Technologists, Medical Imaging Researchers,
Pharmaceutical and Biotech Companies, Biomedical Engineers and MRI
Developers
Learning Objectives:
Upon completion of this activity, participants should be able to:
• A deeper understanding of manganese-based contrast agents and how they
differ from traditional gadolinium-based agents. An opportunity to
compare the benefits and limitations of manganese- and gadolinium-based
agents, gaining a clearer perspective on when to use one over the other;
• A review of recent preclinical and clinical findings on MnPyC3A and
other Mn-based agents, focusing on safety, toxicity, and patient
outcomes;
• A detailed overview of the regulatory hurdles involved in the approval
of new contrast agents and what steps have been taken to bring MnPyC3A
closer to clinical use; and
• Practical guidance on how Mn-based agents could be implemented in
current imaging protocols, as well as tips for optimizing their use in
clinical settings.
|
08:15 |
|
A Glimpse on Recent Progress in Neuro MEMRI
Robia Pautler
|
|
08:45 |
|
MnPyC3A, A Manganese-Based MRI Contrast Agent
Eric Gale
|
|
09:15 |
|
Nano-Theranostics & Antitumor Agents for MRI
Ichio Aoki
|
|
09:45 |
|
Zn2+ & ATP-Responsive Manganese-Based T1 Contrast Agents
Graeme Stasiuk
|
|
10:15 |
|
Improving the Physicochemical Properties of Potential Mn(II)-Based
Liver Specific MRI Probes
Gyula Tircso
|
Back to Meeting Home
Back to the Program-at-a-Glance